Regulatory 2025-12-22 | Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-11-19 | Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program PDF Report Presentation Webcast
Regulatory 2025-11-05 | Quarterly Report Q3 2025: Orviglance NDA Submitted to the FDA PDF Report Presentation Webcast
Regulatory 2025-11-03 | Ascelia Pharma Announces Management Changes to Support Future Growth PDF Report Presentation Webcast
Regulatory 2025-09-02 | Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million PDF Report Presentation Webcast
Regulatory 2025-05-16 | Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission PDF Report Presentation Webcast
Regulatory 2025-05-07 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025 PDF Report Presentation Webcast
Regulatory 2025-04-16 | Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1 PDF Report Presentation Webcast
Regulatory 2025-04-04 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-03-31 | The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025 PDF Report Presentation Webcast
Regulatory 2025-02-25 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025 PDF Report Presentation Webcast
Regulatory 2025-02-12 | Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-02-07 | Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study PDF Report Presentation Webcast
Regulatory 2025-01-30 | NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2024-11-22 | Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program PDF Report Presentation Webcast
Regulatory 2024-11-07 | Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025 PDF Report Presentation Webcast
Regulatory 2024-10-30 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024 PDF Report Presentation Webcast
Regulatory 2024-10-04 | Notice of Extraordinary General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
